why choose us

First received: August 10, 2023

Clinical Trial: Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hidradenitis Suppurativa

Study Type: INTERVENTIONAL


Official Title: A Pilot Study Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo in the Treatment of Moderate-to-severe Hidradenitis Suppurativa (HS).

Brief Summary: The study is a randomized, proof of concept study.30 patients aged 18 and over with HS will be included in this single center, randomized, double-blind, parallel-group study.Dosage of deucravacitinib will be given according to the investigational regimen as follows: 6 mg po bid for 16 weeks.The study compromises a 4-week screening period, a 16-week study period, and a 4-week follow-up period.The follow-up period consists of a follow-up phone call 4 weeks after the last study drug dose.

Read more